| 2025-11-12 |
详情>>
股本变动：
变动后总股本5321.15万股
|
| 2025-11-12 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-1.14美元,归母净利润-5970.5万美元,同比去年增长-67.2%
|
| 2025-10-27 |
详情>>
内部人交易：
Mack David Henry股份增加220643.00股
|
| 2025-08-07 |
详情>>
业绩披露：
2025年中报每股收益-0.74美元,归母净利润-3864.6万美元,同比去年增长-134.46%
|
| 2025-05-09 |
详情>>
业绩披露：
2025年一季报每股收益-0.34美元,归母净利润-1743.6万美元,同比去年增长-14.18%
|
| 2025-04-25 |
股东大会：
将于2025-06-05召开股东大会
会议内容 ▼▲
- 1.To elect two Class II directors, Arnold Levine, Ph.D. and Charles M. Baum, M.D., Ph.D., to hold office until our 2028 annual meeting of stockholders and until their respective successors are elected and qualified;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025;
4.To conduct any other business properly brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2025-03-03 |
详情>>
业绩披露：
2024年年报每股收益-1.14美元,归母净利润-5870.9万美元,同比去年增长14.87%
|
| 2025-03-03 |
详情>>
业绩披露：
2022年年报每股收益-1.61美元,归母净利润-7331.7万美元,同比去年增长-26.75%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.69美元,归母净利润-3570.9万美元,同比去年增长32.88%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-0.32美元,归母净利润-1648.3万美元,同比去年增长54.92%
|
| 2024-08-08 |
详情>>
业绩披露：
2023年中报每股收益-0.8美元,归母净利润-3656.4万美元,同比去年增长-2.3%
|
| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益-0.3美元,归母净利润-1527万美元,同比去年增长20.17%
|
| 2024-04-24 |
股东大会：
将于2024-06-06召开股东大会
会议内容 ▼▲
- 1.To elect two Class I directors, Kirsten Flowers and Carol Gallagher, Pharm.D., to hold office until our 2027 annual meeting of stockholders and until their respective successors are elected and qualified;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024;
4.To conduct any other business properly brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2024-02-29 |
详情>>
业绩披露：
2023年年报每股收益-1.44美元,归母净利润-6896万美元,同比去年增长5.94%
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.13美元,归母净利润-5320.4万美元,同比去年增长1.42%
|
| 2023-10-13 |
复牌提示：
2023-10-12 12:34:06 停牌，复牌日期 2023-10-12 12:39:06
|
| 2023-04-28 |
股东大会：
将于2023-06-08召开股东大会
会议内容 ▼▲
- 1.Election of Richard Heyman, Ph.D., David H. Mack, Ph.D. and Laurie Stelzer as Class III directors
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers
3.Ratification of Ernst & Young LLP as our independent registered public accounting firm
|
| 2022-04-22 |
股东大会：
将于2022-06-02召开股东大会
会议内容 ▼▲
- 1.To elect two Class II directors, Arnold Levine, Ph.D. and Charles M. Baum, M.D., Ph.D., to hold office until our 2025 annual meeting of stockholders and until their respective successors are elected and qualified;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers;
3.To approve, on a non-binding advisory basis, the frequency of future stockholder advisory votes on the compensation of our named executive officers;
4.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2022;
5.To conduct any other business properly brought before the Annual Meeting and any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-23 |
股东大会：
将于2021-06-02召开股东大会
会议内容 ▼▲
- 1.To elect Thilo Schroeder, Ph.D. and Peter Thompson, M.D. as Class I directors until the 2024 annual meeting of stockholders and until their respective successor have been elected or appointed;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.To conduct any other business properly brought before the Annual Meeting and any adjournment or postponement thereof.
|